Drug Interactions between Celestone Phosphate and Tensilon
This report displays the potential drug interactions for the following 2 drugs:
- Celestone Phosphate (betamethasone)
- Tensilon (edrophonium)
Interactions between your drugs
edrophonium betamethasone
Applies to: Tensilon (edrophonium) and Celestone Phosphate (betamethasone)
ADJUST DOSE: Corticosteroids and adrenocorticotropic agents may diminish the therapeutic effects of acetylcholinesterase inhibitors in myasthenia gravis. The mechanism of interaction is unknown. Marked deterioration in muscle strength has been reported in patients with myasthenia gravis shortly after the initiation of corticosteroid therapy, particularly when high dosages were used. In most cases, the decline in muscular function was relatively refractory to acetylcholinesterase inhibitors. However, clinical improvement generally occurs during prolonged corticosteroid therapy when administered properly.
MANAGEMENT: Corticosteroid therapy should be instituted at relatively low dosages (15 to 25 mg/day of prednisone or equivalent) and in a controlled setting in patients with myasthenia gravis. Respiratory support should be available, and the dosage should be increased stepwise as tolerated (approximately 5 mg/day of prednisone or equivalent at 2- to 3-day intervals until marked clinical improvement or a dosage of 50 mg/day is reached). Dose reductions of the acetylcholinesterase inhibitor may be required as symptoms improve, which often may be delayed and gradual.
References
- Namba T (1972) "Corticotropin therapy in patients with myasthenia gravis." Arch Neurol, 26, p. 144-50
- Brunner NG, Namba T, Grob D (1972) "Corticosteroids in management of severe, generalized myasthenia gravis." Neurology, 22, p. 603-10
- Millikan CH, Eaton LM (1951) "Clinical evaluation of ACTH and cortisone in myasthenia gravis." Neurology, 1, p. 145-52
- Patten BM, Oliver KL, Engel WK (1974) "Adverse interaction between steroid hormones and anticholinesterase drugs." Neurology, 24, p. 442-9
- Braunwald E, Hauser SL, Kasper DL, Fauci AS, Isselbacher KJ, Longo DL, Martin JB, eds., Wilson JD (1998) "Harrison's Principles of Internal Medicine." New York, NY: McGraw-Hill Health Professionals Division
Drug and food interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.